Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.750 -0.010 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
28 29 Next >
Psychedelics And Treatment-Resistant Depression: Companies Weigh In On The Important Issue
(Part three of a four-part series) Have a look at previous stories: 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022
Via Benzinga
Psychedelic Drug Stocks Index Continued To Decline Last Week
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter... 
Via Talk Markets
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
(Part one of a four-part series) 
Via Benzinga
COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript
CMPS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Compass Pathways: Q3 Earnings Insights
Compass Pathways (NASDAQ:CMPS) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelics And Treatment-Resistant Depression: Reactions To COMPASS' Published Results
(Part two of a four-part series) See previous story in this series: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS’ Latest Trial Outcomes 
Via Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022
Via Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Clinical Stage Psychedelic Stock Index Up 6%; Therapy Clinic Stocks Down 8%
We highlight the performance of our Psychedelic Drug Stocks Index and the 6 psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of different psychedelic... 
Via Talk Markets
A Comparison Of 5 Psychedelic ETFs And Indices
A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector. 
Via Talk Markets
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 7.91% at $9.96 LOSERS: 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 8, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 3.85% at $0.14 
Via Benzinga
The Psychedelic Drug Stocks Index Continued To Plummet Last Week
In total, the Psychedelic Drug Stock Index went down 5.8% last week and is now down 64.9% YTD. 
Via Talk Markets
Compass Pathways, Allied Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 4.10% at $0.44 
Via Benzinga
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo, Market Subverticals & Informal Guidance
(Part four of a four-part series) See previous stories in this series:  
Via Benzinga
COMPASS Pathways Shares Q3 2022 Financial Results, Business News & Term's Highlights
Psychedelics mental healthcare firm COMPASS Pathways (NASDAQ: CMPS) reported its financial outcomes for the third quarter ended 30 September 2022 and gave an update on its most recent pipeline and... 
Via Benzinga
Psychedelic Stock Gainers And Losers From November 3, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.80% at $10.27 
Via Benzinga
Psyched Wellness is The First Public Company To Bring Amanita Muscaria For Human Consumption To The U.S.
Easily identified by its red cap covered with white dots and a white stem, the Amanita muscaria mushroom is probably the most famous and easily recognizable mushroom in the world. Popularized by Lewis... 
Via Benzinga
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
Compass Pathways's Earnings Outlook
Compass Pathways (NASDAQ:CMPS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Compass... 
Via Benzinga
Why Shares of atai Life Sciences Climbed 14.58% on Tuesday
The company specializes in developing psychedelics as therapies. 
Via The Motley Fool
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities
(Part one of a four-part series) 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback